Literature DB >> 27823948

Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation.

Shimpei Baba1, Yuji Sugawara2, Kengo Moriyama2, Motoki Inaji3, Taketoshi Maehara3, Toshiyuki Yamamoto4, Tomohiro Morio2.   

Abstract

We report the case of on an 8-year-old girl with a cyclin-dependent kinase-like 5 mutation and who underwent vagus nerve stimulation (VNS) therapy for 2years. She had developed epilepsy at the age of 6months and had severe developmental delays. Initially, she had tonic and tonic-clonic seizures; however, around the age of 5years, she also developed epileptic spasms. These seizures were never completely controlled by conventional medical treatments. At the age of 7, after VNS initiation, her seizure frequency markedly reduced, and abnormal electrical activities on her electroencephalography tests strikingly decreased. Moreover, using questionnaires, we confirmed an improvement in her quality of life in the fields of alertness and activity. Although the efficacy of VNS therapy for patients with intractable epilepsy associated with a genetic anomaly has not been fully established, adjunctive VNS therapy may widen the scope of treatment choices available to these patients.
Copyright © 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cycling-dependent kinase-like 5; Epileptic encephalopathy; Quality of life; Vagus nerve stimulation therapy

Mesh:

Substances:

Year:  2016        PMID: 27823948     DOI: 10.1016/j.braindev.2016.10.007

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  5 in total

Review 1.  Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review.

Authors:  Heather E Olson; Scott T Demarest; Elia M Pestana-Knight; Lindsay C Swanson; Sumaiya Iqbal; Dennis Lal; Helen Leonard; J Helen Cross; Orrin Devinsky; Tim A Benke
Journal:  Pediatr Neurol       Date:  2019-02-23       Impact factor: 3.372

Review 2.  CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment.

Authors:  William Hong; Isabel Haviland; Elia Pestana-Knight; Judith L Weisenberg; Scott Demarest; Eric D Marsh; Heather E Olson
Journal:  CNS Drugs       Date:  2022-05-28       Impact factor: 6.497

3.  Refractory Status Epilepticus in Genetic Epilepsy-Is Vagus Nerve Stimulation an Option?

Authors:  Nicola Specchio; Alessandro Ferretti; Nicola Pietrafusa; Marina Trivisano; Costanza Calabrese; Giusy Carfì Pavia; Alessandro De Benedictis; Carlo Efisio Marras; Luca de Palma; Federico Vigevano
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

4.  Vagus nerve stimulation in children with drug-resistant epilepsy of monogenic etiology.

Authors:  Han Xie; Jiayi Ma; Taoyun Ji; Qingzhu Liu; Lixin Cai; Ye Wu
Journal:  Front Neurol       Date:  2022-09-01       Impact factor: 4.086

5.  Novel CDKL5 mutations were found in patients in China: retrospective investigation in cases of CDKL5-related disorders.

Authors:  Yumei Yan; Dake He; Jing Wu; Ruolin Hou; Kun Sun; Ling Li
Journal:  Ital J Pediatr       Date:  2020-02-28       Impact factor: 2.638

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.